Get your community involved in National Ovarian Cancer Awareness Month by writing a Letter to the Editor to your local newspaper! Here’s a template you can start from. #30DaysofTeal To the editor: September is National Ovarian Cancer Awareness Month. Ovarian cancer is one I pay attention to because ovarian cancer has affected my life. [Write … Continued
Donate $10 to the Ovarian Cancer National Alliance today for your chance to win a 2016 Race Experience and meet Danica Patrick and Martin Truex Jr! Two winners will be drawn at the end of September. #TealAppeal #TeamSherry #30DaysofTeal
We are SO EXCITED to announce that we’ve teamed up with Sherry Pollex, ovarian cancer survivor, to launch the Teal Appeal: A campaign dedicated to letting people know that ovaries get cancer too and raise symptom awareness! #30DaysofTeal #TealAppeal #TeamSherry
It’s Wear Teal Day! The ladies of OCNA are out and about today getting creative with TEAL! Show us your TEAL—the awareness color for ovarian cancer—and tell everyone you see a fact about this disease. Share a photo on social media with the hashtag #wearteal to be included in our online roundup. #30DaysofTeal #WearTealDay
Our Survivors Teaching Students: Saving Women’s Lives® program has educated tens of thousands of future health professionals to recognize the signs of ovarian cancer. We need your help to ensure future health professionals are well equipped to recognize and treat this disease. If you are interested in meeting other women changing the face of this … Continued
Check out this guest post by Alan D. D’Andrea, MD, and Elizabeth M. Swisher, MD from the SU2C-OCRF-OCNA-NOCC Dream Team that originally appeared on Cancer Research Catalyst, the official blog of the American Association for Cancer Research, the Scientific Partner of Stand Up 2 Cancer. September is Ovarian Cancer Awareness Month, when we scientists and advocates renew our determination to find new solutions to this devastating disease. This year we are pleased to have seen some encouraging signs. At the Annual Meeting of the American Association for Cancer Research (AACR) in April, scientists reported that a combination of two drugs, olaparib and BKM120, showed clinical benefit for women with high-grade serous ovarian cancer (as well as women with triple-negative breast cancer). Click plus sign to read on.
Ovarian Cancer Research Fund’s Luxury Shopping Event to be held at Grand Canal Shoppes at The Venetian & The Palazzo and Fashion Show, September 19-20 Las Vegas, NV – Ovarian Cancer Research Fund (OCRF) will bring its popular Super Saturday shopping event to Grand Canal Shoppes at The Venetian & The Palazzo, and Fashion Show … Continued
"Ovarian cancer is difficult to detect early -- there is no simple and reliable way to screen for it and symptoms are often not clear until later stages. By recognizing possible warning signs and unexplained changes, women can increase their likelihood of detecting ovarian cancer in its early stages when treatment is most effective and the chances for recovery are greatest. To bolster these efforts, my Administration has continued to invest in innovative research to improve early detection and treatment of ovarian cancer, and we are working hard to increase public awareness among women about all types of gynecological cancers." -President Barack Obama To read more, click the plus sign.
(August 26, 2015) Women with epithelial ovarian cancer who happened to be taking nonselective beta-blockers for hypertension survived longer than those who were not taking the drugs, according to a large multicenter retrospective study. The study was funded in part by an OCRF grant to Dr. Anil Sood at MD Anderson Cancer Center. Survival was … Continued
(August 21, 2015) A study published online in JAMA Oncology this month shows that screening women with a suspected risk of hereditary breast or ovarian cancer with a multigene panel (which looks for mutations in many genes), identifies more people with cancer risk related gene mutations than screening for BRCA1 and 2 alone. Importantly, identifying … Continued
(August 19, 2015) Deleterious mutations in RAD51C and RAD51D genes are associated with increased risk of epithelial ovarian cancer (EOC), according to a study published online Aug. 10 in the Journal of Clinical Oncology. Honglin Song, PhD, from the University of Cambridge in the United Kingdom, and colleagues conducted a genetic study using germline DNA … Continued
(August 19, 2015) Whereas chemotherapy kills cancer cells only while it is being administered, immunotherapy can lead to an adaptive immune response that persists long after treatment is ceased. By simple analogy, whereas aspirin provides temporary pain relief, a polio vaccine provides lifelong protection. Unfortunately, just as tumors develop resistance to conventional therapies, tumors also … Continued
Get email updates about research news, action alerts, and ways to join the fight.
A global, Al-powered ecosystem designed to transform gynecologic cancer research—connecting patients, researchers, and clinicians to accelerate breakthroughs.
Our website uses cookies to ensure you get the best experience. By continuing to use this website, you indicate that you have read and agree to our Terms of Use and Privacy Policy.
